Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas

S. Tura; P. Mazza; F. Gherlinzoni; P. L. Zinzani; G. Poletti; G. Visani; R. M. Lemoli; M. Cavo; P. Galieni; C. Tassi; R. Zanchini

doi:10.1007/BF00273532

Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas

S. Tura, P. Mazza, F. Gherlinzoni, P. L. Zinzani, G. Poletti, G. Visani, R. M. Lemoli, M. Cavo, P. Galieni, C. Tassi, R. Zanchini

A.O.U. San Martino - IST, Istituto Nazionale Ricerca sul Cancro (GENOVA)

Research output: Contribution to journal › Article

Abstract

In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.

Original language	English
Pages (from-to)	123-125
Number of pages	3
Journal	Cancer Chemotherapy and Pharmacology
Volume	23
Issue number	2
DOIs	https://doi.org/10.1007/BF00273532
Publication status	Published - Feb 1989

Fingerprint

ASJC Scopus subject areas

Pharmacology
Oncology
Cancer Research

Cite this

Tura, S., Mazza, P., Gherlinzoni, F., Zinzani, P. L., Poletti, G., Visani, G., Lemoli, R. M., Cavo, M., Galieni, P., Tassi, C., & Zanchini, R. (1989). Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas. Cancer Chemotherapy and Pharmacology, 23(2), 123-125. https://doi.org/10.1007/BF00273532

Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas. / Tura, S.; Mazza, P.; Gherlinzoni, F.; Zinzani, P. L.; Poletti, G.; Visani, G.; Lemoli, R. M.; Cavo, M.; Galieni, P.; Tassi, C.; Zanchini, R.

In: Cancer Chemotherapy and Pharmacology, Vol. 23, No. 2, 02.1989, p. 123-125.

Research output: Contribution to journal › Article

@article{b66007d5796e4ddd85ab95aeb80249c1,

title = "Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas",

abstract = "In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.",

author = "S. Tura and P. Mazza and F. Gherlinzoni and Zinzani, {P. L.} and G. Poletti and G. Visani and Lemoli, {R. M.} and M. Cavo and P. Galieni and C. Tassi and R. Zanchini",

year = "1989",

month = feb

doi = "10.1007/BF00273532",

language = "English",

volume = "23",

pages = "123--125",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas

AU - Tura, S.

AU - Mazza, P.

AU - Gherlinzoni, F.

AU - Zinzani, P. L.

AU - Poletti, G.

AU - Visani, G.

AU - Lemoli, R. M.

AU - Cavo, M.

AU - Galieni, P.

AU - Tassi, C.

AU - Zanchini, R.

PY - 1989/2

Y1 - 1989/2

N2 - In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.

AB - In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.

UR - http://www.scopus.com/inward/record.url?scp=0024271402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024271402&partnerID=8YFLogxK

U2 - 10.1007/BF00273532

DO - 10.1007/BF00273532

M3 - Article

C2 - 2910510

AN - SCOPUS:0024271402

VL - 23

SP - 123

EP - 125

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -

Access to Document

10.1007/BF00273532